Novo Nordisk

An insulin model (Picture credit: Novo Nordisk).

Novo Nordisk defiant despite $90,000 disclosure fine

By Fiona Barry

Novo Nordisk wants “a political debate” and changes to financial disclosure laws after Danish authorities fined it $90,000 for not immediately telling investors the US FDA had rejected Tresiba and Ryzodeg in 2013.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All